Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orenitram Open-Label Extension in PAH
NCT01560637Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2013
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoint: Number of Adverse Events up to 2.5 years. Started Sep 2013; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01560637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01560637.